Nucana Stock Price, News & Analysis

NuCana plc (NASDAQ: NCNA) received a Notification Letter from Nasdaq indicating non-compliance with Listing Rule 5450(a)(1) due to a closing bid price of less than $1.00 per share for 30 consecutive business days.

The company has a 180-day grace period, until November 23, 2022, to regain compliance by achieving a bid price of $1.00 or higher for at least ten consecutive business days. The company's ADSs will continue to trade on Nasdaq during this period, and options to regain compliance are being evaluated.

NuCana plc (NASDAQ: NCNA) announced financial results for Q1 2022, reporting a net loss of £8.4 million, an improvement from £9.8 million in Q1 2021. Cash and equivalents stood at £52.6 million as of March 31, 2022. The company initiated a randomized Phase 2 study of NUC-3373 for colorectal cancer and a Phase 1b/2 study in combination with PD-1 inhibitors. The first patients have been enrolled in the Phase 2 study of NUC-7738. NuCana is well-capitalized with a projected cash runway into 2025, indicating potential for significant clinical milestones.

NuCana plc (NASDAQ: NCNA) announced that Don Munoz, Chief Financial Officer, will hold one-on-one meetings at the Jefferies Healthcare Conference from June 8-10, 2022, in New York, NY. The company focuses on enhancing cancer treatment outcomes through its proprietary ProTide technology, which aims to develop safer and more effective medicines. NuCana’s key product candidates include NUC-3373, in a Phase 1b/2 study for metastatic colorectal cancer, and NUC-7738, in a Phase 1/2 study for advanced solid tumors.

NuCana (NASDAQ: NCNA) reported Q4 and FY 2021 results, revealing a net loss of £40.5 million for the year, higher than the previous year's £30.7 million. As of December 31, 2021, cash reserves were £60.3 million, down from £71 million in Q3 2021. The company plans to launch a Phase 2 study for NUC-3373 in colorectal cancer, aiming for a simplified subsequent Phase 3 study. Additionally, NUC-7738 is advancing into Phase 2, following promising Phase 1 results. NuCana expects a cash runway into 2025, supporting ongoing and upcoming clinical trials.

NuCana plc (NASDAQ: NCNA) announced promising data on its drug NUC-3373 aimed at improving cancer treatment. Presented at the AACR Annual Meeting, the research indicates that NUC-3373 enhances immune response and cell death in colorectal cancer cell lines when combined with nivolumab. Furthermore, NUC-3373 is shown to be more effective than 5-FU, producing higher levels of active metabolites and avoiding its associated toxicities. The company is advancing NUC-3373 into more clinical studies, reinforcing its strategy for treating colorectal cancer.

NuCana plc (NASDAQ: NCNA) has announced the discontinuation of the NuTide:121 study following a futility analysis by its Independent Data Monitoring Committee. Despite a higher objective response rate for Acelarin plus cisplatin, there was no observed overall survival benefit compared to standard treatments. The company remains committed to cancer therapies and is progressing with other candidates, NUC-3373 and NUC-7738, with multiple data readouts expected throughout 2022. The firm emphasizes its robust financial position to support ongoing clinical trials.

NuCana plc (Nasdaq: NCNA) announces participation in two virtual investor conferences. The first is Cowen’s 42nd Annual Healthcare Conference from March 7-9, 2022. The second event is Oppenheimer's 32nd Annual Healthcare Conference on March 16, 2022, at 8:00 AM ET, which will be webcasted live. NuCana focuses on improving cancer treatment through its ProTide technology, with three ProTides in clinical development: Acelarin, NUC-3373, and NUC-7738. Acelarin is in Phase 3 for advanced biliary tract cancer, while NUC-3373 and NUC-7738 are in earlier studies for colorectal and solid tumors.

NuCana plc (NASDAQ: NCNA) announced the completion of patient enrollment for its Phase III NuTide:121 study, which will facilitate a second interim analysis by the second half of 2022. The study is evaluating Acelarin combined with cisplatin against the standard of care, gemcitabine plus cisplatin, for advanced biliary tract cancer. Acelarin's potential for accelerated FDA approval hinges on achieving a statistically significant improvement in the Objective Response Rate (ORR) in interim analyses. The company aims to enroll up to 828 patients in total.

NuCana plc (NASDAQ: NCNA) reported Q3 2021 financial results, noting a cash position of £71.0 million and a net loss of £8.0 million, improving from £8.4 million in Q3 2020.

They completed enrollment of 418 patients for a Phase III study on Acelarin for biliary tract cancer, which may lead to accelerated FDA approval.

The FDA granted Fast Track designation for Acelarin, and positive clinical data for NUC-3373 and NUC-7738 was presented at ESMO 2021.

Several key milestones are anticipated in Q4 2021 and H1 2022.